UF startup DNAtrix and Valo Therapeutics announced an exclusive R&D collaboration to develop enhanced vaccines using DNAtrix’s clinical stage viruses and Valo’s proprietary antigenic peptide technology. DNAtrix’s clinical stage oncolytic adenovirus platform and Valo’s PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus) vaccination technology will be combined to generate a novel “armed oncolytic vaccine” for cancer therapy. While … Continue reading DNAtrix and Valo Therapeutics Enter into Strategic Partnership to Develop Peptide-Coated Oncolytic Viruses for Treating Cancer (PR Newswire)